Skip to main content
. 2022 Jun 14;29(4):570–578. doi: 10.1093/ibd/izac121

Table 4.

Study withdrawal and reason for withdrawal after start of tofacitinib therapy until day 56 (n = 15).

Study withdrawal reason n %
Discontinuation of tofacitinib due to intolerance or adverse event 2 13.3%
Discontinuation of tofacitinib due to lack of efficacy 4 26.7%
Surgery (colectomy) 5 33.3%
Lack of patient’s cooperation with survey completion 3 20.0%
Patient’s request to withdraw from registry 1 6.7%